Key Points
June 23 (Reuters) - In a mid-stage trial, the highest dose of Eli Lilly's (LLY.N) experimental pill orforglipron led to 14.7% weight loss after 36 weeks for people who were obese or overweight, setting a marker in the race to develop effective oral obesity drugs, researchers said on Friday...
Results from a different trial, also presented in San Diego at the annual meeting of the American Diabetes Association, showed that Lilly's injected drug Mounjaro helped people with type 2 diabetes who were also obese or overweight lose an average of 15% of their body weight, or 33 pounds (14.8 kg)...
Both drugs belong to a new class known as incretins that have reignited researcher and investor interest in the weight-loss treatment market, which is estimated to reach $100 billion by the end of the decade...
At the multi-dose trial's 26-week main endpoint, Lilly said once-daily orforglipron showed statistically significant dose-dependent body weight reductions ranging from 8.6% (12mg) to 12.6% (45mg), compared with 2% for the placebo group...
Lilly reported last year that a trial of Mounjaro in people who were obese or overweight but did not have diabetes found it led to weight loss of 22.5%, or about 52 pounds (24kg)...
You might be interested in
Roche enters obesity drugs race with $2.7 bln Carmot deal
04, Dec, 23The race to grab a slice of the lucrative market for obesity treatments is heating up among drugmakers, with Swiss company Roche (ROG.S) becoming one of the latest entrants following its $2.7 billion deal to buy Carmot Therapeutics (CRMO.O).
Drug used to treat diabetes could help obese people lose weight: Study
27, Oct, 23The diabetes drug Mounjaro has helped people with obesity to lose at least a quarter of their body weight, or about 60 pounds on average when combined with intensive diet and exercise, as per a new study.
Ozempic on steroids? Successor that could cut down weight in half the time coming soon
14, Nov, 24While Novo Nordisk says CagriSema will help users lose up to 25% of weight, duration will be clear when final results of its effectiveness in obesity management come out in 3 months.
Eli Lilly: still seeking UK approval on pen for weight-loss drug
09, Nov, 23Eli Lilly (LLY.N) on Thursday said it has not yet gained approval in Britain for the injection pen it plans to use for its Mounjaro drug against obesity and diabetes, adding to uncertainty over timing of the product's launch.
Weight-loss drugs: Who, and what, are they good for?
02, Jan, 24The new drugs are known as GLP-1 agonists, which mimic the activity of a hormone that slows digestion and helps people feel full for longer. In clinical trials, people lost 15% to 20% of their body weight, depending on the drug. Nearly 120 million American adults could be eligible for treatment, while Novo says its target market is more than 760 million people with obesity worldwide.
Lilly experimental 'triple G' obesity drug leads to 24.2% weight loss in trial
27, Jun, 23Eli Lilly on Monday said a mid-stage trial of its next-generation obesity drug candidate "triple G" showed that it led to weight loss of up to 24.2% after 48 weeks, surpassing results seen with other weight loss drugs.